On Thursday, MannKind Corp (MNKD) stock saw a modest uptick, ending the day at $7.02 which represents a slight increase of $0.06 or 0.86% from the prior close of $6.96. The stock opened at $6.96 and ...

Westlake Village-based MannKind saw rising revenue and gave a positive update to its orphan lung pipeline when it announced its earnings for the third quarter of 2024. MannKind, a biotechnology ...

MNKD-201, an inhaled formulation of nintedanib for IPF, was shown to be safe and well tolerated in a clinical trial with ...

MannKind (MNKD) reported $70.08 million in revenue for the quarter ended September 2024, representing a year-over-year increase of 36.7%. EPS of $0.04 for the same period compares to $0.02 a year ago.

As of the latest trading close, MNKD, a Healthcare sector stock, is trading 1.57% below its 52-week high but remains 134.70% above its 52-week low. The Average True Range (ATR) (14 days) of 0.25 ...

MannKind (NASDAQ: MNKD) Q3 2024 Earnings Call Nov 07, 2024, 4:30 p.m. ET ...

MannKind Corp (NASDAQ:MNKD) is set to release its Q3 2024 earnings on Nov 7, 2024. The consensus estimate for Q3 2024 revenue ...

In a report released on November 7, Faisal Khurshid from Leerink Partners reiterated a Buy rating on MannKind (MNKD – Research Report), ...

MannKind (NASDAQ:MNKD – Get Free Report) was upgraded by equities researchers at StockNews.com from a “hold” rating to a “buy” rating in a report issued on Monday. MNKD has been the ...

Shares of MannKind Co. (NASDAQ:MNKD – Get Free Report) have received a consensus recommendation of “Buy” from the seven ...